



August 1, 2024

**BSE Ltd.,**  
P J Towers,  
Dalal Street,  
Mumbai - 400 001.  
**Scrip Code: 524735**

**National Stock Exchange of India Ltd.,**  
Exchange Plaza,  
Bandra-Kurla Complex, Bandra,  
Mumbai - 400 051.  
**Symbol: HIKAL**

Dear Sir/Madam,

**Subject: Earnings Press Release on the Results of the Company for the quarter ended June 30, 2024**

With reference to the subject, we are enclosing a copy of the Press Release on the unaudited Standalone and Consolidated Financial Results of the Company for the quarter ended June 30, 2024.

This is for your information and records.

Thank you,

Yours sincerely,  
**for HIKAL LIMITED,**

**Rajasekhar Reddy**  
**Company Secretary & Compliance Officer**

**Encl: As above**

**Hikal Ltd.**

**Admin. Office:** Great Eastern Chambers, 6<sup>th</sup> Floor, Sector 11, CBD Belapur, Navi Mumbai - 400 614, India. Tel. + 91-22-6277 0299, + 91-22-6866 0300

**Regd. Office:** 717, Maker Chambers - 5, Nariman Point, Mumbai - 400 021, India. Tel. +91-22 6277 0477. Fax: + 91-22 6277 0500


www.hikal.com    info@hikal.com    CIN: L24200MH1988PTC048028

## Q1FY25 EBITDA Margin improved on YoY basis


- ✓ Revenue of Rs. 407 crore
- ✓ EBITDA stood at Rs. 58 crore
- ✓ PAT stood at Rs. 5 crore
- ✓ Hikal's long term credit rating is maintained at A+ by ICRA

**Mumbai, August 1, 2024:** Hikal Ltd., a preferred long-term partner for leading global life sciences companies, announced its unaudited financial results for the quarter ended 30<sup>th</sup> June 2024.

### Q1 FY25 Performance (in Rs. Crore) :



### Pharmaceuticals Division



### Crop-Protection Division



### Q1FY25: Performance Highlights:

- Q1FY25 consolidated Revenue recorded at Rs 407 Crore
- Increased volume demand from existing & new API customers
- Several CDMO project deliveries were pushed back due to customer requirements

### Q1FY25: Pharmaceuticals Performance:

- Revenue Stood at Rs. 229 Crore
- Demand for Own Products is robust
- DMF for 1 product filed during quarter
- 13 customer audits completed successfully during the quarter
- In the last 2 quarters have received a growing number of inquiries
- EBIT Stood at Rs. 9 Crore
- A combination of product mix and scheduled plant maintenance shutdowns leading to lower capacity utilization affected our margins

### Q1FY25: Crop-protection Performance:

- Revenue Stood at Rs. 177 Crore
- Positive traction from several major global innovators in Q1FY25
- 6 CDMO Projects in Pipeline
- Commercialization of the new products developed in last 2-3 years resulted in revenue growth in CDMO business
- Own products witnessed volume uptick
- EBIT stood at Rs. 21 Crore
- Favorable product mix led to an increase in margins year on year
- Global crop protection industry facing challenges: overcapacity and price pressure from competitors, especially China.

**Commenting on the results, Jai Hiremath, Executive Chairman, Hikal Ltd. said,**

*“The global chemical industry is experiencing a recovery in demand, with a steady improvement in consumption, production and capacity utilization. We expect prices to stabilize in the coming quarters. In Q1FY25, our revenues reached Rs. 407 Cr, with an EBITDA of Rs. 58 Cr representing a 5% and 16% growth respectively. This financial improvement was driven by stable raw material prices, as well as our efforts in reducing costs, optimizing processes and diversifying our product range.*

*In Q1 FY25, our pharmaceutical business generated revenue of Rs. 229 Cr, with an EBIT of 3.8%. While we saw an increase in volume demand from existing customers in the API segment, a combination of product mix and scheduled plant maintenance shutdowns leading to lower capacity utilization affected our margins. In the CDMO segment, we continue to receive multiple requests for proposals from emerging pharmaceutical companies and global innovators. Several projects are progressing through to advanced development stages. We have a healthy pipeline of projects in various stages of development.*

*In Q1FY25, our crop protection business generated revenue of Rs. 177 Cr, with an EBIT of 11.9%. While the crop protection market is still challenging, we had a favorable product which led to an increase in margins year on year. With the global crop protection industry facing challenges such as overcapacity and price pressure from competitors, particularly from China, we expect the market to stabilize by the end of this calendar year with volumes recovery.*

*Our animal health business has made significant progress. We have completed the development and validation of five products and are currently on track to finish validating several others by the end of this year. This marks a crucial milestone towards obtaining product registration and eventually launching them commercially in global markets.*

*Under our strategic transformation initiative, Pinnacle, we have achieved significant strides in sustaining growth across our different business segments. We have focused on reducing risks in our supply chain, developing unique capabilities, acquiring new customers, and building a distinctive technology platform. As we move forward with our strategic plan, we will prioritize front-end opportunities to build and commercialize a robust pipeline across business segments.*

*Despite ongoing global challenges, we are confident that market conditions will improve in this financial year. Our primary objective is to achieve profitable and sustainable growth in all our business segments. We are committed to adapting our strategies to meet changing market conditions and to capitalize on the growing list of emerging opportunities.”*

## About Hikal Limited

Hikal is a reliable long-term partner to companies in the Pharmaceuticals, Crop Protection, and Specialty Chemicals industry. The company is in the business of supplying research services, active ingredients and intermediates, manufactured using stringent global quality standards, for its global customers. Hikal's advanced manufacturing facilities have been inspected and approved by leading multinational companies in the Crop protection and Pharmaceutical sectors. The Crop protection facilities are located at Taloja, Mahad (Maharashtra) and Panoli (Gujarat). Hikal's R&T facilities are located at Pune. The Pharmaceutical manufacturing facilities are situated in Jigani (Bengaluru) and Panoli (Gujarat). Hikal is the first Indian life-sciences company to receive the Responsible Care® certification governed by the International Council of Chemical Associations (ICCA).

## Safe Harbor Statement

Statements in this document relating to future status, events, or circumstances, including but not limited to statements about plans and objectives, the progress and results of research and development, potential project characteristics, project potential and target dates for project related issues are forward-looking statements based on estimates and the anticipated effects of future events on current and developing circumstances. Such statements are subject to numerous risks and uncertainties and are not necessarily predictive of future results. Actual results may differ materially from those anticipated in the forward-looking statements. The company assumes no obligation to update forward-looking statements to reflect actual results changed assumptions or other factors.

For further information, please contact

### Company :

#### Hikal Limited

CIN: L24200MH1988PTC048028

Mr. Anish Swadi

[anish\\_swadi@hikal.com](mailto:anish_swadi@hikal.com)

[www.hikal.com](http://www.hikal.com)

### Investor Relations Advisors :

#### Strategic Growth Advisors Pvt. Ltd.

CIN: U74140MH2010PTC204285

Mr. Jigar Kavaiya

[jigar.kavaiya@sgapl.net](mailto:jigar.kavaiya@sgapl.net)

+91 9920602034

Ms. Ami Parekh

[ami.parekh@sgapl.net](mailto:ami.parekh@sgapl.net)

+91 8082466052

[www.sgapl.net](http://www.sgapl.net)